Aleksandra Łacko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleksandra Łacko has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Michal Jarzab
Breast Cancer Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
2 shared publications Agnieszka Młodzińska
Maria Sklodowska-Curie National Research Institute of Oncology Department of Breast Cancer and Reconstructive Surgery Warsaw 02-781
1 shared publication- Aleksandra Konieczna
Maria Sklodowska-Curie National Research Institute of Oncology Department of Breast Cancer and Reconstructive Surgery Warsaw 02-781
1 shared publication Anika PęKala
Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology Department of Proliferative Diseases Lodz 95-513
1 shared publication- Anna Polakiewicz-Gilowska
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Breast Cancer Center Gliwice 44-102
1 shared publication - Barbara Radecka
Department of Oncology, Institute of Medical Sciences, University of Opole, 45-052 Opole, Poland
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Challenges in breast cancer prevention knowledge and training: identifying gaps among medical trainees
Introduction: Breast cancer is the most common malignancy among women in Poland, yet participation in the national mammography screening programme remains low (approximately 30%). Medical trainees play a crucial role in promoting prevention, but their preparation in this area is insufficiently explored. Material and methods: A cross-sectional online survey was conducted among students from 10 Polish medical universities and doctors-in-training (from November 2024 to February 2025). The questionnaire assessed knowledge of screening guidelines, exposure to curricular training, and self-reported competence in clinical breast examination (CBE). Descriptive statistics and tests were used to analyse associations between categorical variables. Results: A total of 1,245 participants were included. Nearly half (48.7%) had never been taught CBE, and only 4% had practised with patients. While most respondents recognised mammography as an effective screening tool (96.4%), only 24.1% correctly identified both the screening interval and eligible age group. Attendance at curricular classes was significantly associated with better knowledge, higher confidence in performing CBE independently (p < 0.001), and greater comfort discussing breast self-examination with patients (85% vs. 76%, p < 0.001). Conclusions: This nationwide study highlights major gaps in breast cancer prevention education among Polish medical trainees. Although general awareness of mammography is high, understanding of programme details and practical CBE skills remains limited. Structured, competency-based curricula incorporating hands-on and simulation-based training are needed to strengthen preventive oncology education and support efforts to increase screening participation in Poland.
- 6 October 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Open AccessChallenges in breast cancer prevention knowledge and training: identifying gaps among medical trainees
Introduction: Breast cancer is the most common malignancy among women in Poland, yet participation in the national mammography screening programme remains low (approximately 30%). Medical trainees play a crucial role in promoting prevention, but their preparation in this area is insufficiently explored. Material and methods: A cross-sectional online survey was conducted among students from 10 Polish medical universities and doctors-in-training (from November 2024 to February 2025). The questionnaire assessed knowledge of screening guidelines, exposure to curricular training, and self-reported competence in clinical breast examination (CBE). Descriptive statistics and tests were used to analyse associations between categorical variables. Results: A total of 1,245 participants were included. Nearly half (48.7%) had never been taught CBE, and only 4% had practised with patients. While most respondents recognised mammography as an effective screening tool (96.4%), only 24.1% correctly identified both the screening interval and eligible age group. Attendance at curricular classes was significantly associated with better knowledge, higher confidence in performing CBE independently (p < 0.001), and greater comfort discussing breast self-examination with patients (85% vs. 76%, p < 0.001). Conclusions: This nationwide study highlights major gaps in breast cancer prevention education among Polish medical trainees. Although general awareness of mammography is high, understanding of programme details and practical CBE skills remains limited. Structured, competency-based curricula incorporating hands-on and simulation-based training are needed to strengthen preventive oncology education and support efforts to increase screening participation in Poland.
- Open Access
- 20 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study
Background: Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited. Materials and methods: We conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: <65 vs ≥65 years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety. Results: Among 303 patients, 76 (25.1%) were aged ≥65 years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status ≥1. In unadjusted analyses, patients aged ≥65 years had longer median OS (12.8 vs 10.9 months; HR, 0.70; 95% CI, 0.49-0.99; P = 0.045) and PFS (5.4 vs 4.1 months; HR, 0.73; 95% CI, 0.54-0.97; P = 0.031). ORR, DCR, treatment modifications, and grade ≥3 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS. Conclusion: In this selected real-world cohort, patients aged ≥65 years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.
- 20 July 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Open AccessClinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study
Background: Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited. Materials and methods: We conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: <65 vs ≥65 years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety. Results: Among 303 patients, 76 (25.1%) were aged ≥65 years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status ≥1. In unadjusted analyses, patients aged ≥65 years had longer median OS (12.8 vs 10.9 months; HR, 0.70; 95% CI, 0.49-0.99; P = 0.045) and PFS (5.4 vs 4.1 months; HR, 0.73; 95% CI, 0.54-0.97; P = 0.031). ORR, DCR, treatment modifications, and grade ≥3 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS. Conclusion: In this selected real-world cohort, patients aged ≥65 years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.